Sichenzia Ross Friedman Ference LLP Advises Tonix Pharmaceuticals on $7.8 Million Public Offering
NEW YORK, July 16, 2014 (GLOBE NEWSWIRE) –New York based securities law firm, Sichenzia Ross Friedman Ference LLP, acted as counsel to Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a clinical-stage pharmaceutical company focused on researching common disorders of the central nervous system, on a recently completed $7.8 million registered direct public offering pursuant to Tonix’s shelf registration statement. The offering consisted of 657,000 shares of common stock sold at $11.90 per share. Roth Capital Partners acted as the sole placement agent in this offering. The Sichenzia Ross Friedman Ference LLP team consisted of partners Marc J. Ross and James M. Turner and associate Sharon Carroll.
Visit SRF's LinkedIn page
Latest posts by Sichenzia Ross Ference LLP (see all)
- Attorneys Selected for Inclusion on 2019 Super Lawyers Lists - October 16, 2019
- Sichenzia Ross Ference LLP to Join Client Relmada Therapeutics, Inc. at Nasdaq Opening Bell Ringing - October 15, 2019
- Sichenzia Ross Ference LLP Congratulates Relmada Therapeutics, Inc., on NASDAQ Uplisting - October 10, 2019